By adding this new patent family to the already large Intellectual Property portfolio protecting its products, ArcticZymes has further improved its strong proprietary position on this field.
"This latest patent approval secures our existing position and opens new markets for our highly innovative products. The first approval is a strong indication that other patents in this patent family will follow, forming a strong fundament for our commercial efforts in the field," says CEO Svein Lien in Biotec Pharmacon.
ArcticZymes AS develops, produces and sells enzymes used in molecular DNA technologies and diagnostics. The market is highly expansive, and the rapid and diversifying technological development creates a strong market demand for new and improved enzymes.
distributed by |